Skip to main content
AmigoFish

Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

From BioSpace · · 20 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.

Back to BioSpace · Report a problem